Terms ending in 2041
Every in-force patent on The Institut Pasteur's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,759,516 | NUCLEIC ACID VACCINE AGAINST THE SARS-CoV-2 CORONAVIRUS In force · High confidence | Institut Pasteur | In force | High confidence | |
| US 11,911,462 | Nucleic Acid Vaccine Against the SARS-COV-2 Coronavirus In force · High confidence | Institut Pasteur | In force | High confidence | |
| US 11,964,013 | Nucleic Acid Vaccine Against the SARS-COV-2 Coronavirus In force · High confidence | Institut Pasteur | In force | High confidence | |
| US 11,969,467 | Nucleic Acid Vaccine Against the SARS-COV-2 Coronavirus In force · High confidence | Institut Pasteur | In force | High confidence | |
| US 12,171,827 | Nucleic Acid Vaccine Against the SARS-COV-2 Coronavirus In force · High confidence | Institut Pasteur | In force | High confidence | |
| US 12,324,834 | Nucleic Acid Vaccine Against the SARS-COV-2 Coronavirus In force · High confidence | Institut Pasteur | In force | High confidence | |
| US 12,753,245 | Luciferase Linked Immunosorbent Assay Institut Pasteur, Institut National de la Sante et de la Recherche Medicale and Centre National de la Recherche Scientifique In force · Medium confidence | Institut Pasteur, Institut National de la Sante et de la Recherche Medicale and Centre National de la Recherche Scientifique | In force | Medium confidence | |
| US 12,065,461 | Method for Preparing 3'-O-Amino-2'-Deoxyribonucleoside-5'-Triphosphate In force · High confidence | Institut Pasteur and Centre National de la Recherche Scientifique | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.